Verastem Initiates Phase 1 Trial of Dual mTOR/PI3K Inhibitor

Verastem VSTM today announced the initiation of a Phase 1 trial of VS-5584, a dual mTORC1/2 and PI3K inhibitor, in patients with advanced solid tumors or lymphoma. “Initiation of the clinical development of VS-5584 is an important milestone for Verastem,” said Dr. Joanna Horobin, Verastem Chief Medical Officer. “We are conducting this study with clinical investigators who have extensive experience with PI3K and mTOR inhibitors and applying our expertise in cancer stem cell biology to progress the development of the compound.” Verastem presented preclinical research at the American Association See full press release